Team 11 : reMoVE-B (CRCI2NA)

Team 11 : reMoVE-B (CRCI2NA) is a leading research services provider dedicated to understanding and overcoming the molecular vulnerabilities that tumors develop to escape detection and treatment. Focusing on mature B-cell malignancies, Team 11 : reMoVE-B (CRCI2NA) conducts groundbreaking research into the hallmarks of cancer, including dysregulation of cell cycle, apoptosis, and epigenetic remodeling, all of which originate from both the tumor itself and its surrounding microenvironment. These insights provide a foundation for identifying and targeting cancer cell adaptations, enhancing the potential for innovative therapeutic interventions.

With a focus on major molecular mechanisms implicated in cancer cell resistance and escape, Team 11 : reMoVE-B (CRCI2NA) specializes in areas such as the p53 pathway, BCL2 family, and epigenetic modifiers networks. The team leverages original culture models, including ex vivo co-culture models and patient-derived xenografts (PDX), alongside cutting-edge technologies like Multispectral IHC, multiparameter flow cytometry, and scRNASeq. Their work in hematology and related specialties has positioned Team 11 : reMoVE-B (CRCI2NA) at the forefront of cancer research.

Team 11 : reMoVE-B (CRCI2NA) is committed to advancing the fight against cancer by identifying vulnerabilities that can be exploited for therapeutic gain. With a strong foundation in research and innovative methodologies, Team 11 : reMoVE-B (CRCI2NA) continues to push the boundaries of cancer research. We invite the manager of Team 11 : reMoVE-B (CRCI2NA) to create a customized and exclusive company showcase and product listing on our platform to further highlight their exceptional work.